Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and sb 203580

lapatinib has been researched along with sb 203580 in 8 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(sb 203580)		Trials
(sb 203580)		Recent Studies (post-2010) (sb 203580)
1,9193051,4423,48941,137

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)sb 203580 (IC50)
Citron Rho-interacting kinaseHomo sapiens (human)1
Cyclin-G-associated kinaseHomo sapiens (human)0.4133
Mitogen-activated protein kinase 13Homo sapiens (human)0.2329
Mitogen-activated protein kinase 2Pneumocystis carinii0.105
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)1.0359
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)0.7575
Cytochrome P450 1A2Homo sapiens (human)2
Tyrosine-protein kinase LckHomo sapiens (human)3.45
Neutrophil elastaseHomo sapiens (human)0.025
Cytochrome P450 3A4Homo sapiens (human)0.062
Cytochrome P450 2D6Homo sapiens (human)2
TyrosinaseMus musculus (house mouse)0.034
Cholesteryl ester transfer proteinHomo sapiens (human)0.04
Cytochrome P450 2C9 Homo sapiens (human)1
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)5
Serine/threonine-protein kinase B-rafHomo sapiens (human)1
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)0.36
Prostaglandin G/H synthase 1Homo sapiens (human)2
Thromboxane-A synthase Homo sapiens (human)0.494
Adenosine receptor A2aHomo sapiens (human)6.068
Ephrin type-B receptor 2Homo sapiens (human)7.8
Adenosine receptor A1Homo sapiens (human)2.95
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)0.01
Delta-type opioid receptorMus musculus (house mouse)0.02
Cytochrome P450 2C19Homo sapiens (human)0.8
TGF-beta receptor type-1Homo sapiens (human)6
Mitogen-activated protein kinase 9Homo sapiens (human)0.9517
Mitogen-activated protein kinase 14 Mus musculus (house mouse)0.056
Casein kinase I isoform deltaHomo sapiens (human)0.4147
Casein kinase I isoform epsilonHomo sapiens (human)1
Mitogen-activated protein kinase 12Homo sapiens (human)0.2329
Mitogen-activated protein kinase 10Homo sapiens (human)0.6933
Mitogen-activated protein kinase 1Rattus norvegicus (Norway rat)0.048
Myotonin-protein kinaseHomo sapiens (human)1
Mitogen-activated protein kinase 11Homo sapiens (human)0.2646
Mitogen-activated protein kinase 14Homo sapiens (human)0.39
P2X purinoceptor 7Homo sapiens (human)5
Serine/threonine-protein kinase 36Homo sapiens (human)1
Serine/threonine-protein kinase NLKHomo sapiens (human)1
TRAF2 and NCK-interacting protein kinaseHomo sapiens (human)1

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's6 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Russu, WA; Shallal, HM1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Al-Mazaideh, GM; Erdmann, F; Göllner, C; Rohe, A; Schmidt, M; Sippl, W; Wichapong, K1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Abd Elmageed, ZY; Abdel Latif, NA; Abdelhafez, OM; Ahmed, EY; Ali, HI; Arafa, RK1

Other Studies

8 other study(ies) available for lapatinib and sb 203580

ArticleYear
A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nature biotechnology, 2005, Volume: 23, Issue:3

    Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines

2005
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
    European journal of medicinal chemistry, 2013, Volume: 61

    Topics: Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Glycolipids; Humans; Membrane Proteins; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship

2013
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Design and molecular modeling of novel P38α MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds.
    Bioorganic & medicinal chemistry, 2019, 04-01, Volume: 27, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Biological Products; Breast Neoplasms; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Heterocyclic Compounds; Humans; MCF-7 Cells; Mitogen-Activated Protein Kinase 14; Models, Molecular; Molecular Structure; Oxygen; Protein Kinase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured

2019